News
Cizzle Bio News
Stay informed with the latest updates on Cizzle Bio's milestones, industry news, and significant events. Here, you will find:
Latest
Cizzle Bio, Inc. Partners with Moffitt Cancer Center to Advance Lung Cancer Detection
Cizzle Bio, Inc. is proud to collaborate with Moffitt Cancer Center to clinically evaluate the CIZ1B biomarker test for early-stage lung cancer detection. This partnership represents a significant step in advancing lung cancer diagnostics and improving patient care.
Revolutionizing Lung Cancer Detection: Cizzle Bio, Inc.'s New Partnership
Cizzle Bio, Inc. announces a groundbreaking partnership with Cizzle Biotechnology Holdings PLC, ushering in a new era of lung cancer detection technology in North America. Learn about how the advanced CIZ1B biomarker is set to change the landscape of healthcare.
ProteoGenix and Cizzle Biotechnology Collaboration Advances Early Lung Cancer Detection
ProteoGenix and Cizzle Biotechnology have developed new antibodies for early lung cancer detection. Explore the advancements and future impacts of this innovative partnership.
Strategic Licensing and Partnership: Cizzle Bio Inc.
Discover how Cizzle Biotechnology's new partnership aims to revolutionize lung cancer detection in North America through the CIZ1B biomarker test. Learn more about the strategic licensing agreement and its benefits.
NCI’s new Deputy Director for Data Science, Dr. Warren Kibbe, aims to revolutionize cancer research using AI and big data. Learn about his goals and their impact on cancer detection and treatment advancements.